A Phase II Trial of Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-Cell Lymphoma (BENCART): A Consortium for Improving Survival of Lymphoma (CISL) Trial

被引：0
|
作者：
Park, Byeong-Bae [1 ]
Kim, Won Seog [2 ]
Suh, Cheolwon [3 ]
Yoon, Dok Hyun [3 ]
Won, Jong-Ho [4 ]
Yang, Deok-Hwan [5 ]
Do, Young-Rok [6 ]
Lee, Won Sik [7 ]
Kim, Jeong-A [8 ]
Kim, Min Kyoung [9 ]
Jo, Jae-Cheol [10 ]
Koh, Youngil [11 ]
机构：
[1] Hanyang Univ, Coll Med, Seoul, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[4] Soonchunhyang Univ, Coll Med, Seoul, South Korea
[5] Chonnam Natl Univ Hwasun Hosp, Dept Hematol Oncol, Hwasun, South Korea
[6] Dongsan Med Ctr, Daegu, South Korea
[7] Inje Univ, Coll Med, Busan, South Korea
[8] Catholic Univ Korea, St Vincents Hosp, Suwon, South Korea
[9] Yeungnam Univ Med Ctr, Daegu, South Korea
[10] Univ Ulsan, Coll Med, Ulsan Univ Hosp, Ulsan, South Korea
[11] Seoul Natl Univ Hosp, Seoul, South Korea
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.1823.1823
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1823
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma
    Zinzani, Pier Luigi
    Musuraca, Gerardo
    Tani, Monica
    Stefoni, Vittorio
    Marchi, Enrica
    Fina, Mariapaola
    Pellegrini, Cinzia
    Alinari, Lapo
    Derenzini, Enrico
    de Vivo, Antonio
    Sabattini, Elena
    Pileri, Stefano
    Baccarani, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (27) : 4293 - 4297
  • [22] Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma
    Querfeld, Christiane
    Kuzel, Timothy M.
    Kim, Youn H.
    Porcu, Pierluigi
    Duvic, Madeleine
    Musiek, Amy
    Rook, Alain H.
    Mark, Lawrence A.
    Pinter-Brown, Lauren
    Hamid, Oday
    Lin, Boris
    Bian, Ying
    Boye, Mark
    Day, Jeannette M.
    Rosen, Steven T.
    LEUKEMIA & LYMPHOMA, 2011, 52 (08) : 1474 - 1480
  • [23] PHASE II STUDY OF SMILE CHEMOTHERAPY FOR RELAPSED/ REFRACTORY PERIPHERAL T-CELL LYMPHOMA
    Suzuki, R.
    Hyo, R.
    Kim, W. S.
    Tsukamoto, N.
    Maeda, Y.
    Masaki, Y.
    Sakai, R.
    Masunari, T.
    Niitsu, N.
    Ishida, F.
    Nakamura, S.
    Suzumiya, J.
    HAEMATOLOGICA, 2015, 100 : 401 - 401
  • [24] A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
    Bennani, N. Nora
    Pederson, Levi D.
    Atherton, Pamela
    Micallef, Ivana
    Colgan, Joseph P.
    Thanarajasingam, Gita
    Nowakowski, Grzegorz
    Witzig, Thomas E.
    Feldman, Andrew L.
    Ansell, Stephen M.
    BLOOD, 2019, 134
  • [25] Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108
    Barr, Paul M.
    Li, Hongli
    Spier, Catherine
    Mahadevan, Daruka
    LeBlanc, Michael
    Haq, Mansoor Ul
    Huber, Bryan D.
    Flowers, Christopher R.
    Wagner-Johnston, Nina D.
    Horwitz, Steven M.
    Fisher, Richard I.
    Cheson, Bruce D.
    Smith, Sonali M.
    Kahl, Brad S.
    Bartlett, Nancy L.
    Friedberg, Jonathan W.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (21) : 2399 - U105
  • [26] Chidamide Plus Prednisone, Cyclophosphamide, and Thalidomide (CPCT) for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Multicenter Phase II Trial
    Xu, Wei
    Liang, Jin-Hua
    Wang, Li
    Wang, Xiao-Dong
    Cui, Guohui
    Zhou, Jianfeng
    Xu, Jingyan
    Wang, Luqun
    Liang, Rong
    Chen, Bi-yun
    Cheng, Jian
    Li, Jian-Yong
    BLOOD, 2022, 140 : 9484 - 9485
  • [27] Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma
    Kumar, Anita
    Vardhana, Santosha
    Moskowitz, Alison J.
    Porcu, Pierluigi
    Dogan, Ahmet
    Dubovsky, Jason A.
    Matasar, Matthew J.
    Zhang, Zhigang
    Younes, Anas
    Horwitz, Steven M.
    BLOOD ADVANCES, 2018, 2 (08) : 871 - 876
  • [28] A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Activity in T-cell lymphoma.
    Mehta-Shah, Neha
    Lunning, Matthew Alexander
    Boruchov, Adam M.
    Ruan, Jia
    Nair, Sumithra
    Lynch, Peggy
    Byrne, Regina
    Moskowitz, Alison J.
    Matasar, Matthew J.
    Gerecitano, John F.
    Hamlin, Paul A.
    Leonard, John
    Moskowitz, Craig H.
    Myskowski, Patricia L.
    Querfeld, Christiane
    Nolan, Patrick
    Palomba, Maria Lia
    Straus, David J.
    Zelenetz, Andrew David
    Horwitz, Steven M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Phase II Trial of Romidepsin as Consolidation Therapy after Gemcitabine, Dexamethasone, and Cisplatin in Elderly Transplant-Ineligible Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
    Yamasaki, Satoshi
    Iida, Hiroatsu
    Saito, Akio
    Matsumoto, Morio
    Kuroda, Yoshiaki
    Izumi, Tohru
    Saito, Akiko M.
    Miyoshi, Hiroaki
    Ohshima, Koichi
    Nagai, Hirokazu
    Iwasaki, Hiromi
    HEMATOLOGY REPORTS, 2024, 16 (02) : 336 - 346
  • [30] Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial
    Mehta-Shah, Neha
    Zinzani, Pier Luigi
    Jacobsen, Eric D.
    Zain, Jasmine
    Mead, Monica
    Casulo, Carla
    Gritti, Giuseppe
    Pinter-Brown, Lauren C.
    Izutsu, Koji
    Bentur, Ohad S.
    Sidransky, David
    Brammer, Jonathan E.
    Pro, Barbara
    Fox, Christopher P.
    Horwitz, Steven
    BLOOD, 2024, 144 : 3061 - 3062
12345